Literature DB >> 32267484

Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review.

Martin P Paulus1,2, Jennifer L Stewart1,2.   

Abstract

Importance: The prevalence of and mortality associated with methamphetamine use has doubled during the past 10 years. There is evidence suggesting that methamphetamine use disorder could be the next substance use crisis in the United States and possibly worldwide. Observation: The neurobiology of methamphetamine use disorder extends beyond the acute effect of the drug as a monoaminergic modulator and includes intracellular pathways focused on oxidative stress, neurotoxic and excitotoxic effects, and neuroinflammation. Similarly, the clinical picture extends beyond the acute psychostimulatory symptoms to include complex cardiovascular and cerebrovascular signs and symptoms that need to be identified by the clinician. Although there are no pharmacologic treatments for methamphetamine use disorder, cognitive behavioral therapy, behavioral activation, and contingency management show modest effectiveness. Conclusions and Relevance: There is a need to better understand the complex neurobiology of methamphetamine use disorder and to develop interventions aimed at novel biological targets. Parsing the disorder into different processes (eg, craving or mood-associated alterations) and targeting the neural systems and biological pathways underlying these processes may lead to greater success in identifying disease-modifying interventions. Finally, mental health professionals need to be trained in recognizing early cardiovascular and cerebrovascular warning signs to mitigate the mortality associated with methamphetamine use disorder.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32267484     DOI: 10.1001/jamapsychiatry.2020.0246

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  35 in total

Review 1.  Understanding Stimulant Use and Use Disorders in a New Era.

Authors:  Daniel Ciccarone; Steve Shoptaw
Journal:  Med Clin North Am       Date:  2022-01       Impact factor: 5.456

2.  Cortical thickness and related depressive symptoms in early abstinence from chronic methamphetamine use.

Authors:  Johannes Petzold; Andy C Dean; Jean-Baptiste Pochon; Dara G Ghahremani; Richard De La Garza; Edythe D London
Journal:  Addict Biol       Date:  2022-09       Impact factor: 4.093

3.  Differences in small-world networks between methamphetamine and heroin use disorder patients and their relationship with psychiatric symptoms.

Authors:  Yan Liu; Qiang Li; Tianyi Zhang; Lei Wang; Yarong Wang; Jiajie Chen; Jia Zhu; Hong Shi; Wei Wang; Wei Li
Journal:  Brain Imaging Behav       Date:  2022-08-26       Impact factor: 3.224

4.  Methamphetamine Use: A Narrative Review of Adverse Effects and Related Toxicities.

Authors:  Amber N Edinoff; Sarah E Kaufman; Keionne M Green; Daniel A Provenzano; Jesse Lawson; Elyse M Cornett; Kevin S Murnane; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-09-15

Review 5.  Chemokines, cytokines and substance use disorders.

Authors:  Olivia C Ahearn; Mia N Watson; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2021-01-08       Impact factor: 4.492

6.  Non-fatal stimulant overdose among homeless and unstably housed women in San Francisco, California.

Authors:  Thibaut Davy-Mendez; Eric Vittinghoff; Samantha E Dilworth; Leslie W Suen; Carl Braun; Phillip O Coffin; Derek D Satre; Elise D Riley
Journal:  Drug Alcohol Depend       Date:  2021-09-22       Impact factor: 4.492

Review 7.  Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction.

Authors:  Christopher M Jones; Debra Houry; Beth Han; Grant Baldwin; Alana Vivolo-Kantor; Wilson M Compton
Journal:  Ann N Y Acad Sci       Date:  2021-09-24       Impact factor: 6.499

8.  Female rats display higher methamphetamine-primed reinstatement and c-Fos immunoreactivity than male rats.

Authors:  Steven T Pittenger; Shinnyi Chou; Nathen J Murawski; Scott T Barrett; Olivia Loh; Juan F Duque; Ming Li; Rick A Bevins
Journal:  Pharmacol Biochem Behav       Date:  2021-01-08       Impact factor: 3.697

9.  Roflumilast treatment during forced abstinence reduces relapse to methamphetamine seeking and taking.

Authors:  James J Baek; Hannah Kline; Carmen M Deveau; Bryan K Yamamoto
Journal:  Addict Biol       Date:  2021-08-07       Impact factor: 4.280

Review 10.  Neurotoxicity of methamphetamine: Main effects and mechanisms.

Authors:  Subramaniam Jayanthi; Atul P Daiwile; Jean Lud Cadet
Journal:  Exp Neurol       Date:  2021-06-26       Impact factor: 5.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.